Review Article
Peripheral T-Cell Lymphoma: Review and Updates of Current Management Strategies
Table 3
Selected results of high-dose chemotherapy and autologous stem cell transplantation in PTCL.
| Study | N | Regimen | Response | OS | Comments |
| Retrospective series |
| Rodríguez et al. [33] | 115 | BEAM/BEAC/CVB/Cy + TBI | 86% CR, 5% PR | 56% at 5 y | PTCL | Yamazaki et al. [34] | 11 | CEM/HD-MTX | 91% CR, 9% PR | 72% at 3 y | No ALCL | Schetelig et al. [35] | 14 | Diverse | 86% CR | 60% at 5 y | AITL only | Kyriakou et al. [36] | 146 | Diverse | 70% CR, 7% PR | 59% at 4 y | AITL only |
| Prospective |
| Rodríguez et al. [37] | 13 | BEAM | 65% CR, 4% PR | 48% at 3 y | Subgroup analysis | Mercadel et al. [38] | 41 | High-dose CHOP/ESHAP | 51% CR, 7% PR | 29% at 4 y | 41% received ASCR | D’ Amore et al. [39] | 77 | BEAM | 71% CR/PR | No data | 75% received ASCR | Reimer et al. [40] | 83 | Cy/TBI | 58% CR, 8% PR | 48% at 3 y | 66% received ASCR |
|
|